Intensity‑Modulated Radiotherapy (IMRT) — Medical Coverage Policy
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs the medical coverage and criteria for use of intensity-modulated radiotherapy (IMRT) for various cancer sites and payer products for Blue Cross Blue Shield - Rhode Island.
No material clinical or coverage changes in this revision.
Coverage Criteria for IMRT
inv-01: Abdomen, Pelvis and Chest
Covered when ANY of the following clinical situations are met as specified below.
Bladder requires BOTH primary non-metastatic AND curative intent
inv-02: Breast
Covered when ONE of the following is met.
Demonstration required despite use of complex positioning device (eg, Vac-Lok)
inv-03: Central Nervous System
Covered when ALL of the following are met for CMS tumors and hippocampal-avoidance.
inv-04: Head, Neck, Thyroid
Covered when listed site-specific tumors or proximity criteria are met.
inv-05: Lung
Covered when ALL of the following are met.
Example: from 40% down to 30% or lower
inv-06: Prostate
Covered when ANY of the following are met.
inv-07: Sarcomas
Covered when ANY of the following conditions are met.
inv-08: Medically Necessary Indications / Evidence-supported uses
IMRT is considered medically appropriate when clinical evidence or dosimetric considerations indicate improved net health outcome or reduction in toxicity for the following:
Evidence includes randomized trials, nonrandomized comparative studies, systematic reviews, dosimetry studies, and case series.
inv-09: Selective indications based on proximity to organs at risk
Situations where IMRT may be appropriate based on dosimetry or consensus:
Intensity-modulated radiotherapy (IMRT) is not covered for Medicare Advantage Plans and is considered not medically necessary for Commercial Products for certain indications where evidence is insufficient. Specifically, IMRT is not covered or considered not medically necessary when used: as a technique of partial-breast irradiation after breast-conserving surgery; as a technique of postmastectomy irradiation; to deliver radiotherapy for individuals receiving palliative treatment for lung cancer; and for all other indications not listed in the medical criteria section.
Coverage and payment for IMRT are determined by the member’s benefits and eligibility documents. This policy is provided for informational purposes and is not a guarantee of payment; the member’s subscriber agreement, member certificate, and/or employer agreement supersede the policy. For member‑specific benefit information, providers should contact the BCBSRI provider call center.
The coverage stance differs by product: for the non-covered indications listed above, IMRT is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products. Providers should apply the product‑specific coverage rules when determining medical necessity and billing.
If services are determined to be not medically necessary or a non‑covered benefit, providers may not charge the member for those services unless the member has been informed and has agreed in writing in advance to accept financial responsibility. Refer to participation agreements and member documents for applicable billing and charge rules.
Billing and Code Information
| A4648 | Tissue marker, implantable, any type, each (Note: This code is not separately reimbursed for institutional providers) |
| 77301 | Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications |
| 77338 | Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan |
| 77385 | Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple (Institutional providers) |
| 77386 | Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex (Institutional providers) |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session (Professional providers) |
| G6016 | Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session (Professional providers) |
Provider Requirements, Prior Authorization & Documentation
Prior authorization required for MA; recommended for Commercial
Prior authorization must be obtained for Medicare Advantage members; for Commercial products, providers are strongly advised to use the insurer’s online prior authorization tool when participating in the network.
Covered IMRT CPT/HCPCS codes when criteria met
The listed IMRT planning and delivery CPT/HCPCS codes are covered for Medicare Advantage and Commercial products only when the medical criteria in this policy are met.
Document attempt/compare 3D‑CRT planning or show IMRT dosimetry benefit
When IMRT is proposed based on dosimetric advantage, providers should demonstrate that a standard 3D‑CRT plan cannot meet normal tissue dose‑volume constraints or provide a dosimetry comparison showing that IMRT achieves the policy‑specified absolute reductions (for example, lung V20 reduction of ≥10% absolute or breast heart volume reductions per criteria).
- Example lung threshold: 3D plan V20 >35% and IMRT reduces V20 by ≥10% absolute (e.g., 40% → 30%).
- Example breast threshold: 3D‑CRT predicts heart V25 ≥ 10 cm3 and IMRT reduces volume receiving ≥25 Gy by ≥20% absolute.
Submit complete supporting documentation to justify medical necessity
Ensure all required supporting documentation is submitted with authorization/billing to justify medical necessity and to avoid potential denials.
- Provide clinical rationale and dosimetry comparisons when IMRT is used to demonstrate criteria are met.
- Be aware that interventions outside the listed indications may be considered not covered and subject to denial.
Provide CT/MRI delineation, dose‑volume constraints, and IMRT dosimetry
Treatment planning documentation must include CT‑based delineation of target volumes and organs at risk (and MRI when applicable), explicit dose‑volume constraints, and IMRT dosimetry showing the expected dose reductions versus the 3D‑CRT plan when used to justify IMRT.
- Dose‑volume histograms and specified normal tissue tolerance limits should be included in the plan documentation.
Submit clinical notes and invoice for A4648 to ensure correct pricing
For correct pricing of HCPCS code A4648 (Calypso 4D localization system), submit the procedure/clinical notes and the invoice along with the claim; include procedure‑specific documentation supporting use of listed IMRT codes when criteria are met.
- A4648 is listed as a tissue marker code and requires notes plus invoice to ensure correct pricing.
Non‑covered indications may be denied and not billable to members without written agreement
IMRT for the listed non‑covered indications (e.g., partial‑breast irradiation after breast‑conserving surgery, postmastectomy irradiation, palliative lung radiotherapy, and indications not in the medical criteria) may be denied; services deemed not medically necessary or non‑covered benefits may not be billable to members unless the member was informed and agreed in writing.
- Do not bill members for denied/non‑covered services unless prior written informed consent/agreement is documented.
- Verify member benefits and eligibility; coverage is subject to the subscriber/employer agreement.
Denial/charge risk for NMN or non‑covered services
If services are determined to be not medically necessary or otherwise non‑covered, expect claim denial and do not charge the member unless the member was informed and agreed in writing beforehand.
- Check participation agreements and member benefit documents before billing the member for non‑covered services.
Background and Rationale
Background: IMRT is an advanced external‑beam radiotherapy technique that uses CT and MRI imaging with computer‑optimized inverse planning and multileaf collimators to modulate beam intensity across multiple beamlets. The intent is to improve dose conformality to complex tumor volumes and spare adjacent organs at risk compared with conventional 3D conformal radiotherapy (3D‑CRT); variants include volumetric modulated arc therapy (VMAT) and other image‑guided delivery approaches.
Definitions
Revision History
Policy published as Provider Update (June 2023).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.